Oral estramustine and oral etoposide for hormone-refractory prostate cancer.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Urology

• Publication date

  1997-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0090-4295(97)00323-3PMID 9372887
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. Danish Prostatic Cancer Group.

  1997cited by this paper
• The price of success.

  1995cited by this paper
• Effect of flutamide withdrawal on response assessment of estramustine and etoposide for prostate cancer.

  1995cited by this paper
• Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.

  1994cited by this paper
• Oral etoposide in the treatment of hormone‐refractory prostate cancer

  1994cited by this paper
• Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer.

  1994cited by this paper
• Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix.

  1993cited by this paper
• Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer.

  1993cited by this paper
• Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, genitourinary group prospective randomized phase III study (30865).

  1993cited by this paper
• Cytotoxic chemotherapy for advanced hormone‐resistant prostate cancer

  1993cited by this paper
• Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.

  1993cited by this paper
• Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer.

  1992cited by this paper
• Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.

  1992cited by this paper
• Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs.

  1988cited by this paper
• Chemotherapy for prostatic carcinoma.

  1988cited by this paper
• Evaluation of survival data and two new rank order statistics arising in its consideration.

  1966cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Nanomedicine for prostate cancer using nanoemulsion: A review

  2017cites this paper
• Oral Chemotherapy in the Treatment of Hormone-Refractory Prostate Cancer

  2012cites this paper
• Investigation of Novel Progression-related Methylation Events and HOXD Genes in Prostate Cancer

  2012cites this paper
• Treatment Options in Hormone-Refractory Prostate Cancer

  2012cites this paper
• Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer.

  2011cites this paper
• Oral Chemotherapy in Hormone-Refractory Prostate Carcinoma Patients Unwilling to Be Admitted to Hospital

  2009cites this paper
• Small-cell prostate carcinoma: A retrospective analysis of five newly reported cases

  2009cites this paper
• Advantages of second line estramustine for overall survival of hormone-refractory prostate cancer (HRPC) patients.

  2009cites this paper
• Review: Cooperative group trials — Southwest Oncology Group (SWOG) innovations in advanced prostate cancer

  2009cites this paper
• Out-patient low-dose oral chemotherapy in hormone refractory prostate carcinoma (HRPC) patients unfit for hospital admittance.

  2008cites this paper
• Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer.

  2008cites this paper
• Outcome of patients with hormone-refractory prostate cancer: prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen.

  2008cites this paper
• Relapsed prostate cancer with neuroendocrine differentiation and high serum levels of carcinoembryonic antigen without elevation of prostrate‐specific antigen: A case report

  2007cites this paper
• [Prostate cancer and chemotherapy].

  2007cites this paper
• Urological cancers in clinical practice

  2007cites this paper
• Topoisomerase II-α expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma

  2006cites this paper
• Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.

  2006cites this paper
• Changing perspectives of the role of chemotherapy in advanced prostate cancer.

  2006cites this paper
• LOW-DOSE ORAL CHEMOTHERAPY FOR HORMONE-REFRACTORY PROSTATE CARCINOMA (HRPC). ESTRAMUSTINE PHOSPHATE VERSUS ESTRAMUSTINE PHOSPHATE AND ETOPOSIDE. A RANDOMISED PHASE II STUDY OF GSTU FOUNDATION

  2006cites this paper
• Interleukin-31: a new cytokine involved in inflammation of the skin.

  2006cites this paper
• Combination chemotherapy with estramustine phosphate, ifosfamide and cisplatin for hormone-refractory prostate cancer.

  2006cites this paper
• Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.

  2006cites this paper
• Chemotherapy in Prostate Cancer

  2005cites this paper
• Prior estrogen therapy as a predictor of response to subsequent estramustine-based chemotherapy in patients with androgen-independent prostate cancer.

  2005cites this paper
• Original article Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: A phase II study with a 5-year follow-up

  2005cites this paper
• New standards in the chemotherapy of metastatic hormone-refractory prostate cancer

  2005cites this paper
• Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities.

  2005cites this paper
• Prospective Study of Estramustine Phosphate for Hormone Refractory Prostate Cancer Patients following Androgen Deprivation Therapy

  2005cites this paper
• A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer

  2005cites this paper
• Clinical trials in metastatic prostate cancer--has there been real progress in the past decade?

  2005cites this paper
• Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up.

  2005cites this paper
• Stratégies thérapeutiques actuelles du cancer de la prostate hormonorésistant

  2004cites this paper
• Thromboembolic events with estramustine phosphate‐based chemotherapy in patients with hormone‐refractory prostate carcinoma

  2004cites this paper
• Phase II Trial of Estramustine and Etoposide in Androgen-Sensitive Metastatic Prostate Carcinoma

  2004cites this paper
• Prevention and management of prostate cancer chemotherapy complications.

  2004cites this paper
• Therapieoptionen beim Prostatakarzinom

  2004cites this paper
• Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study.

  2004cites this paper
• The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.

  2003cites this paper
• Role of Chemotherapy in Hormone-Refractory Prostate Cancer

  2003cites this paper
• Bi‐weekly epirubicin, etoposide and low‐dose dexamethasone for hormone‐refractory prostate cancer

  2003cites this paper
• The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.

  2003cites this paper
• Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone‐refractory prostate carcinoma

  2003cites this paper
• Pharmacotherapy of hormone refractory prostate cancer: new developments and challenges

  2003cites this paper
• Chemotherapie beim hormonrefraktären Prostatakarzinom

  2003cites this paper
• Current strategies in the management of hormone refractory prostate cancer.

  2003cites this paper
• Prostate cancer and bone metastases: medical treatment.

  2003cites this paper
• [Chemotherapy of hormone refractory prostate carcinoma].

  2003cites this paper
• Is There a Standard Chemotherapeutic Regimen for Hormone-Refractory Prostate Cancer? Present and Future Approaches in the Management of the Disease

  2003cites this paper
• Optimizing targeted therapy and developing novel outcome measures for patients with advanced prostate cancer at Memorial Sloan-Kettering Cancer Center.

  2003cites this paper
• Chapter 46 – Androgen-independent Prostate Cancer: The Evolving Role of Chemotherapy

  2003cites this paper
• Estramustine Phosphate Sodium

  2003cites this paper
• Chemotherapy for the Treatment of Hormone-Refractory Prostate Cancer

  2002cites this paper
• Highlights of contemporary issues in the medical management of prostate cancer.

  2002cites this paper
• EMP combination chemotherapy and low-dose monotherapy in advanced prostate cancer

  2002cites this paper
• Chemotherapy for prostate cancer.

  2002cites this paper
• Advanced Prostate Cancer

  2002cites this paper
• Controversies in chemotherapy of prostate cancer.

  2002cites this paper
• LÉČBA HORMONÁLNĚ REFRAKTERNÍHO METASTAZUJÍCÍHO KARCINOMU PROSTATY

  2001cites this paper
• Weekly high-dose calcitriol and docetaxel in advanced prostate cancer.

  2001cites this paper
• A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407) *

  2001cites this paper
• APhaseIITrialofEstramustineandEtoposide inHormoneRefractoryProstateCancer: ASouthwestOncologyGroupTrial(SWOG9407)

  2001cites this paper
• Prostate Cancer Chemotherapy

  2001cites this paper
• The treatment challenge of hormone-refractory prostate cancer.

  2001cites this paper
• Il Trattamento Chemioterapico Del Carcinoma Prostatico: Ruolo Potenziale Del Docetaxel

  2001cites this paper
• Docetaxel in prostate cancer.

  2001cites this paper
• Systemic treatment and new developments in advanced prostate cancer.

  2001cites this paper
• The role of chemotherapy in prostate cancer. Minireview.

  2000cites this paper
• Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK).

  2000cites this paper
• Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress?

  2000cites this paper
• Chemotherapy for hormone‐refractory prostate cancer: Beauty is in the eye of the beholder

  2000cites this paper
• Novel strategies and therapeutics for the treatment of prostate carcinoma

  2000cites this paper
• Oral estramustine phosphate and oral etoposide for the treatment of hormone‐refractory prostate cancer

  2000cites this paper
• New Paradigms in the Management of Hormone Refractory Disease

  2000cites this paper
• Etoposide in prostate cancer

  2000cites this paper
• Activation of the tumor metastasis suppressor gene, KAI1, by etoposide is mediated by p53 and c-Jun genes.

  2000cites this paper
• Recent advances in chemotherapy for advanced prostate cancer

  2000cites this paper
• Immunohistochemical staining for DNA topoisomerase II‐alpha in benign, premalignant, and malignant lesions of the prostate

  2000cites this paper
• Advances in prostate cancer.

  1999cites this paper
• Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer.

  1999cites this paper
• Current Chemotherapy Regimens: What Oncologists Are Using

  1999cites this paper
• Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer.

  1999cites this paper
• Treatment of prostate cancer

  1999cites this paper
• Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer.

  1999cites this paper
• Hormone-refractory prostate cancer: an evolving standard of care.

  1999cites this paper
• Recent advances in the treatment of prostate cancer.

  1999cites this paper
• Chemotherapy of advanced prostatic carcinoma.

  1999cites this paper
• Chemotherapy for hormone refractory prostate cancer.

  1999cites this paper
• Hormone Resistance in Prostate Cancer

  1998cites this paper
• APhase IITrialof Estramustine and Etoposide

  year unknowncites this paper